{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "NCT04179760",
            "NStudiesAvail": 430108,
            "NStudiesFound": 2,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 2,
            "FieldList": [
                  "ResultsFirstSubmitDate",
                  "ResultsFirstSubmitQCDate",
                  "RetractionPMID",
                  "RetractionSource",
                  "SamplingMethod",
                  "SecondaryId",
                  "SecondaryIdDomain",
                  "SecondaryIdLink",
                  "SecondaryIdType",
                  "SecondaryOutcomeDescription",
                  "SecondaryOutcomeMeasure",
                  "SecondaryOutcomeTimeFrame",
                  "SeeAlsoLinkLabel",
                  "SeeAlsoLinkURL",
                  "SeriousEventAssessmentType",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "An EASI score is a tool used to measure the extent (area) and severity of atopic eczema (Eczema Area and Severity Index). The minimum EASI score is 0 and the maximum EASI score is 72. Higher scores mean worse outcome.",
                              "An EASI score is a tool used to measure the extent (area) and severity of atopic eczema (Eczema Area and Severity Index). The minimum EASI score is 0 and the maximum EASI score is 72. Higher scores mean worse outcome.",
                              "An EASI score is a tool used to measure the extent (area) and severity of atopic eczema (Eczema Area and Severity Index). The minimum EASI score is 0 and the maximum EASI score is 72. Higher scores mean worse outcome.",
                              "This assessment is the overall investigator's overall global assessment for the whole body. Minimum 0 to Maximum 4. 0 means No inflammatory signs of atopic dermatitis, 4 means Marked erythema & Disease is widespread in extent.",
                              "This assessment is the overall investigator's overall global assessment for the whole body. Minimum 0 to Maximum 4. 0 means No inflammatory signs of atopic dermatitis, 4 means Marked erythema & Disease is widespread in extent.",
                              "The NRS is comprised of two items and represents the numbers 0 (\"no itch\") to 10 (\"worst imaginable itch\") in the average score of itch and the worst score of itch.",
                              "The NRS is comprised of two items and represents the numbers 0 (\"no itch\") to 10 (\"worst imaginable itch\") in the average score of itch and the worst score of itch.",
                              "BSA involvement of AD will be assessed for each part of the body using \"Wallace rule of nines\". This BSA is not calculated by weight and height unlike usual BSA calculation, the Wallace rule of nines is a tool used in pre-hospital and emergency medicine to estimate the total body surface area (BSA) affected by a burn. However, this study, the rule of nines will be used to measure the estimated BSA of atopic dermatitis.",
                              "SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). Dermatologists may use this tool before and after treatment to determine whether the treatment has been effective. Maximum value is up to 103 which is the worst outcome.",
                              "The Dermatology Life Quality Index questionnaire is designed for use in adults. The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.",
                              "POEM scores are 0-2 (clear/almost clear); 3-7 (mild); 8-16 (moderate); 17-24 (severe); 25-28 (very severe)",
                              "biomarkers will be evaluated from the baseline to each time point. Unit of Measure is IU/mL.",
                              "biomarkers will be evaluated from the baseline to each time point. Unit of measure is cells/\u03bcL.",
                              "biomarkers will be evaluated from the baseline to each time point. Unit of measure is pg/mL.",
                              "biomarkers will be evaluated from the baseline to each time point. Unit of measure is pg/mL.",
                              "biomarkers will be evaluated from the baseline to each time point. Unit of measure is pg/mL.",
                              "biomarkers will be evaluated from the baseline to each time point. Unit of measure is pg/mL."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Score change from Baseline in Eczema Area and Severity Index(EASI) score",
                              "Percentage of subjects who have EASI-75 (improvement of \u226575% in EASI score from Baseline)",
                              "Percentage of subjects who have EASI-90 (improvement of \u226590% in EASI score from Baseline)",
                              "Percentage of subjects who have the Investigator's Global Assessment (IGA) score of 0 or 1",
                              "Percentage of subjects whose Investigator Global Assessment (IGA) score is decreased by 2 points or more",
                              "Score change from Baseline on Pruritus Numerical Rating Scale (NRS)",
                              "Percentage of subjects whose Pruritus Numerical Rating Scale (NRS) is improved by 3 points or more",
                              "Percentage change from Baseline in Body Surface Area (BSA) affected by Atopic Dermatitis (AD)",
                              "Score change from Baseline in the SCORing Atopic Dermatitis (SCORAD) index",
                              "Score change from Baseline in the Dermatology Life Quality Index (DLQI)",
                              "Score change from Baseline the Patient-Oriented Eczema Measure (POEM)",
                              "Change from Baseline in biomarker (Immunoglobulin E [IgE])",
                              "Change from Baseline in biomarker (eosinophil count)",
                              "Change from Baseline in biomarker (interleukin [IL]-13)",
                              "Change from Baseline in biomarker (interleukin [IL]-17)",
                              "Change from Baseline in biomarker (thymus and activation-regulated chemokine [TARC])",
                              "Change from Baseline in biomarker (interleukin [IL]-22)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Weeks 4, 8, 12, 16, 20 and 24",
                              "Weeks 12, 16, 20 and 24",
                              "Weeks 12, 16, 20 and 24",
                              "Weeks 12, 16, 20 and 24",
                              "Weeks 12, 16, 20 and 24",
                              "Weeks 4, 8, 12, 16, 20 and 24",
                              "Weeks 12, 16, 20 and 24",
                              "Weeks 4, 8, 12, 16, 20 and 24",
                              "Weeks 4, 8, 12, 16, 20 and 24",
                              "Weeks 4, 8, 12, 16, 20 and 24",
                              "Weeks 4, 8, 12, 16, 20 and 24",
                              "Week 4, Week 6, Week 8, Week 12, Week 16, Week 20 and Week 24",
                              "Week 4, Week 6, Week 8, Week 12, Week 16, Week 20 and Week 24",
                              "Week 4, Week 6, Week 8, Week 12, Week 16, Week 20 and Week 24",
                              "Week 4, Week 6, Week 8, Week 12, Week 16, Week 20 and Week 24",
                              "Week 4, Week 6, Week 8, Week 12, Week 16, Week 20 and Week 24",
                              "Week 4, Week 6, Week 8, Week 12, Week 16, Week 20 and Week 24"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04179760"
                        ]
                  },
                  {
                        "Rank": 2,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [
                              "Non-Probability Sample"
                        ],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Number of abnormality in general appearance, skin, eyes/ears/nose/throat, head and neck, cardiovascular, respiratory, abdomen, extremities, lymph nodes, musculoskeletal and neurologic.",
                              "Hematology panel: alkaline phosphatase [ALP], blood urea nitrogen, creatinine, serum aspartate aminotransferase (AST), serum alanine aminotransferase (ALT), albumin, total protein, total bilirubin, uric acid, glucose, cholesterol, sodium, potassium, chloride, calcium, phosphorus",
                              "Chemistry panel: hemoglobin, hematocrit, red blood cells, white blood cells (WBC), WBC differential count, platelets",
                              "Urinalysis panel: specific gravity (SG), color, pH, protein, glucose, bilirubin, blood, WBC"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Outcome of unresolved Adverse Events(AEs) from ADT2002 study",
                              "Clinically important physical examination findings",
                              "Number of occurrence of Abnormal, clinically significant in hematology laboratory results",
                              "Number of occurrence of Abnormal, clinically significant in chemistry laboratory results",
                              "Number of occurrence of Abnormal, clinically significant in urinalysis laboratory results"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Up to 5 Years",
                              "Up to 5 Years",
                              "Up to 5 Years",
                              "Up to 5 Years",
                              "Up to 5 Years"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04185584"
                        ]
                  }
            ]
      }
}